Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04129216 · ClinicalTrials.gov registry record · Phase 2
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04129216: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT04129216 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04129216, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.
Interventions
- DRUG Letrozole
- DRUG Exemestane
- DRUG Tamoxifen Citrate
- DIAGNOSTIC_TEST Blueprint
- DIAGNOSTIC_TEST Mammaprint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-02-20 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04129216
The ClinicalTrials.gov registry entry for NCT04129216 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Letrozole is the first listed.
NCT04129216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04129216 about?
NCT04129216 is a clinical study titled "The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer". The investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.
What is the current status of trial NCT04129216?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-02-20. Estimated completion is 2022-11-10.
What interventions are being tested in trial NCT04129216?
The interventions under investigation include: Letrozole (DRUG), Exemestane (DRUG), Tamoxifen Citrate (DRUG), Blueprint (DIAGNOSTIC_TEST), Mammaprint (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04129216?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.